Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a recombinant human growth hormone presented as a solution for injection for subcutaneous use. It is indicated for treating growth hormone deficiency and related growth disorders in children and adults.

GNH USA supplies Norditropin Flexpro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Clients benefit from comprehensive regulatory support and timely delivery across multiple regions.

Norditropin Flexpro, a recombinant human growth hormone, is used to address conditions characterized by insufficient endogenous growth hormone activity. - Growth hormone deficiency: promotes linear growth and improves metabolic parameters in children and adults with confirmed deficiency. - Turner syndrome: supports height increase and body composition improvements in girls with Turner syndrome. - Chronic renal insufficiency: enhances growth velocity in pediatric patients with renal failure. - Prader‑Willi syndrome: aids in improving body composition and growth outcomes. - Idiopathic short stature: facilitates height gain in children with unexplained short stature.

Somatropin therapy may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site pain or erythema. - Headache. - Joint stiffness or arthralgia. - Peripheral edema. - Transient hyperglycemia. - Fatigue.

Serious or Rare Side Effects: - Intracranial hypertension. - Slipped epiphysis (growth plate injury). - Pancreatitis. - Severe allergic reaction, including anaphylaxis. - Abnormal glucose metabolism progressing to diabetes. - Potential increased risk of tumor recurrence or new malignancy.

When prescribing Norditropin Flexpro, clinicians should observe several precautionary measures to ensure safe and effective use. - Dose titration: adjust based on IGF‑1 levels and growth response. - Monitoring: conduct regular assessments of glucose, thyroid, and cortisol status. - Contraindications: avoid use in patients with active malignancy. - Pregnancy and lactation: consider only if potential benefits outweigh risks. - Pediatric growth monitoring: watch for accelerated epiphyseal closure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Glucocorticoids: may reduce somatropin effectiveness. - Estrogen therapy: can increase IGF‑1 levels and risk of adverse effects. - Insulin: may exacerbate hyperglycemia. - Diabetes medications: risk of unpredictable glucose control.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may alter IGF‑1 dynamics. - Thyroid hormone replacement: requires monitoring of thyroid function. - CYP450 inducers (e.g., rifampin): potential impact on hormone metabolism. - Anti‑epileptic drugs: may affect growth hormone action.